Clinical Trials Browser

Breast Neoplasms, Breast Neoplasms, Male, Triple Negative Breast Neoplasms

Breast Neoplasms, Breast Neoplasms, Male

Breast Neoplasms, Breast Neoplasms, Male, Triple Negative Breast Neoplasms

Breast Neoplasms, Male

Breast Neoplasms, Breast Neoplasms, Male, Triple Negative Breast Neoplasms

Breast Neoplasms, Breast Neoplasms, Male

Neoplasm Metastasis, Endometrial Neoplasms, Breast Neoplasms, Male, Triple Negative Breast Neoplasms

Breast Neoplasms, Breast Neoplasms, Male, Cardiotoxicity

Breast Neoplasms, Breast Neoplasms, Male

Breast Neoplasms, Breast Neoplasms, Male, Cardiotoxicity

Breast Neoplasms, Colonic Neoplasms, Melanoma, Rectal Neoplasms, Teratoma, Testicular Neoplasms, Breast Neoplasms, Male

Breast Neoplasms, Breast Neoplasms, Male

Breast Neoplasms, Breast Neoplasms, Male

Breast Carcinoma In Situ, Breast Neoplasms, Carcinoma, Intraductal, Noninfiltrating, Breast Neoplasms, Male

Breast Neoplasms, Breast Neoplasms, Male

Breast Neoplasms, Breast Neoplasms, Male, Inflammatory Breast Neoplasms

Breast Neoplasms, Breast Neoplasms, Male

Breast Neoplasms, Breast Neoplasms, Male

Breast Neoplasms, Breast Neoplasms, Male

Breast Neoplasms, Breast Neoplasms, Male

Breast Neoplasms, Breast Neoplasms, Male

Breast Neoplasms, Breast Neoplasms, Male, Triple Negative Breast Neoplasms

Brain Neoplasms, Breast Neoplasms, Neoplasm Metastasis, Breast Neoplasms, Male

Breast Neoplasms, Breast Neoplasms, Male

Breast Neoplasms, Breast Neoplasms, Male

Breast Neoplasms, Breast Neoplasms, Male

Breast Neoplasms, Breast Neoplasms, Male

Breast Neoplasms, Carcinoma, Ductal, Breast, Breast Neoplasms, Male

Breast Neoplasms, Breast Neoplasms, Male, Inflammatory Breast Neoplasms

Breast Neoplasms, Neoplasm Metastasis, Breast Neoplasms, Male

Breast Neoplasms, Breast Neoplasms, Male

Breast Neoplasms, Breast Neoplasms, Male

Breast Neoplasms, Breast Neoplasms, Male

Breast Neoplasms, Breast Neoplasms, Male, Triple Negative Breast Neoplasms

Breast Neoplasms, Breast Neoplasms, Male

Breast Neoplasms, Breast Neoplasms, Male

Breast Neoplasms, Carcinoma, Ductal, Breast, Carcinoma, Lobular, Breast Neoplasms, Male, Inflammatory Breast Neoplasms

Breast Neoplasms, Breast Neoplasms, Male

Breast Neoplasms, Breast Neoplasms, Male

Breast Neoplasms, Breast Neoplasms, Male

Breast Neoplasms, Breast Neoplasms, Male, Triple Negative Breast Neoplasms

Breast Neoplasms, Breast Neoplasms, Male

Breast Neoplasms, Breast Neoplasms, Male

Breast Neoplasms, Breast Neoplasms, Male

Breast Neoplasms, Breast Neoplasms, Male

Breast Neoplasms, Breast Neoplasms, Male

Brain Neoplasms, Breast Neoplasms, Neoplasm Metastasis, Breast Neoplasms, Male, Meningeal Carcinomatosis

Breast Neoplasms, Breast Neoplasms, Male, Carcinoma, Ductal

Clinical Trials

Paclitaxel With or Without Carboplatin and/or Bevacizumab Followed by Doxorubicin and Cyclophosphamide in Treating Patients With Breast Cancer That Can Be Removed by Surgery

Paclitaxel Albumin-Stabilized Nanoparticle Formulation in Treating Patients of Different Ages With Metastatic Breast Cancer

Azacitidine and Entinostat in Treating Patients With Advanced Breast Cancer

PePPy

Targeted T Cells After Neoadjuvant Chemotherapy in Treating Women With Stage II or III Breast Cancer Undergoing Surgery

Gemcitabine +/- Imatinib Mesylate, Patients w/Previously Treated Metastatic Breast Cancer

ONC201 in Recurrent/Refractory Metastatic Breast Cancer and Advanced Endometrial Carcinoma

Doxorubicin and Cyclophosphamide Followed By Trastuzumab, Paclitaxel, and Lapatinib in Treating Patients With Early-Stage HER2-Positive Breast Cancer That Has Been Removed By Surgery

Bicalutamide in Treating Patients With Metastatic Breast Cancer

Lisinopril or Coreg CR® in Reducing Side Effects in Women With Breast Cancer Receiving Trastuzumab

Phase II Trial of the Cyclin-Dependent Kinase Inhibitor PD 0332991 in Patients With Cancer

Sorafenib and Paclitaxel in Treating Patients With Metastatic Breast Cancer

Capecitabine and Radiation Therapy in Treating Patients With Nonmetastatic Breast Cancer After Surgery

Omega-3 Fatty Acid in Treating Patients With Stage I-III Breast Cancer

Docetaxel, Carboplatin, Trastuzumab, and Lapatinib in Treating Patients With Early Stage Breast Cancer

Sunitinib Malate, Paclitaxel, Doxorubicin Hydrochloride, and Cyclophosphamide Before Surgery in Treating Patients With Stage IIB-IIIC Breast Cancer

Cyclophosphamide and Vaccine Therapy With or Without Trastuzumab in Treating Patients With Metastatic Breast Cancer

Trastuzumab, Cyclophosphamide, and Vaccine Therapy in Treating Patients With High-Risk or Metastatic Breast Cancer

Neo-adjuvant Therapy With Anastrozole Plus Pazopanib in Stage II and III ER+ Breast Cancer

Fulvestrant and Bevacizumab in Treating Patients With Metastatic Breast Cancer

Pixantrone Dimaleate in Treating Patients With HER2-Negative Metastatic Breast Cancer

Brostallicin and Cisplatin in Treating Patients With Metastatic Breast Cancer

Irinotecan and Temozolomide in Treating Patients With Breast Cancer Who Have Received Previous Treatment for Brain Metastases

Sorafenib and Fulvestrant in Treating Patients With Locally Advanced or Metastatic Breast Cancer That Did Not Respond to Aromatase Inhibitor Therapy

Topical Imiquimod and Abraxane in Treating Patients With Advanced Breast Cancer

Allogeneic Natural Killer (NK) Cells in Patients With Advanced Metastatic Breast Cancer

Lapatinib and Tamoxifen in Treating Patients With Locally Advanced or Metastatic Breast Cancer That Did Not Respond to Previous Tamoxifen

Cryoablation Therapy in Treating Patients With Invasive Ductal Breast Cancer

Combination Chemotherapy and Peripheral Blood Stem Cell Transplant Followed By Aldesleukin and Sargramostim in Treating Patients With Inflammatory Stage IIIB or Metastatic Stage IV Breast Cancer

S0622, Dasatinib in Treating Patients With Stage IV Breast Cancer That Has Spread to the Bone

Lapatinib Ditosylate and Radiation Therapy in Treating Patients With Locally Advanced or Locally Recurrent Breast Cancer

Doxorubicin and Cyclophosphamide Followed by Paclitaxel, Trastuzumab, and Lapatinib in Treating Patients With HER2/Neu-Overexpressed Breast Cancer

Paclitaxel Albumin-Stabilized Nanoparticle Formulation, Gemcitabine, and Bevacizumab in Treating Patients With Metastatic Breast Cancer

Gamma-secretase/Notch Signalling Pathway Inhibitor RO4929097 in Treating Patients With Advanced, Metastatic, or Recurrent Triple Negative Invasive Breast Cancer

Epirubicin and Vinorelbine in Treating Patients With Stage II, Stage III, or Stage IV Breast Cancer

Capecitabine, Vinorelbine, and Trastuzumab in Treating Patients With Metastatic Breast Cancer

Combination Chemotherapy With or Without Trastuzumab Followed By an Autologous Stem Cell Transplant and Radiation Therapy in Treating Patients With Stage III or Stage IV Breast Cancer

Erlotinib Plus Docetaxel in Treating Patients With Stage IV or Recurrent Breast Cancer

Agatolimod and Trastuzumab in Treating Patients With Locally Advanced or Metastatic Breast Cancer

A Phase II Study of AZD2171 in Breast Cancer Stage IV (10006202)

Cisplatin and Paclitaxel With or Without Everolimus in Treating Patients With Stage II or Stage III Breast Cancer

Suberoylanilide Hydroxamic Acid in Treating Patients With Progressive Stage IV Breast Cancer

GTI-2040 and Capecitabine in Treating Patients With Metastatic Breast Cancer

Trastuzumab, Ixabepilone, and Carboplatin in Treating Patients With HER2/Neu-Positive Metastatic Breast Cancer

Bevacizumab and Combination Chemotherapy in Patients With Lymph Node Positive Breast Cancer

Saracatinib in Treating Patients With Metastatic or Locally Advanced Breast Cancer That Cannot Be Removed By Surgery

Epothilone B in Treating Patients With CNS Metastases From Breast Cancer

Pemetrexed as the First Treatment in Advanced or Metastatic Breast Cancer